Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Current and Projected Market Size of the Tuberculosis Therapeutics Market Through 2034?

The market size of tuberculosis therapeutics has experienced considerable growth in the past few years. Projected expansion from $1.88 billion in 2024 to $2 billion in 2025, with a compound annual growth rate of 6.6%, signifies robust growth. Factors that contributed to the growth in the historical timeframe include growing frequency of tuberculosis, increased acceptance of tuberculosis therapeutics, heightened awareness of tuberculosis, rising prevalence of XDR-TB, and an upswing in drug-resistant tuberculosis cases.

Anticipated robust expansion is seen in the tuberculosis therapeutics market size over the upcoming years. It is projected to surge to$2.55 billion in 2029″ with a compound annual growth rate (CAGR) of 6.2%. The predicted expansion throughout the forecast period is due to factors such as elevated investment in healthcare framework, increased knowledge and education, rising funding for research and development, increased endorsement of various anti-TB drugs, augmentation in research grants, and an increasing count of elderly populations. Notable trends for the forecast period comprise advancements in drug formulations, customized medical treatment, combed therapeutic strategies, digital health improvements, and augmentation of AI and machine learning in pharmaceutical exploration.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20983&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Tuberculosis Therapeutics Market?

The growth of the tuberculosis therapeutics market is projected to be fueled by the increasing prevalence of co-infections of tuberculosis (TB) and human immunodeficiency virus (HIV). The term co-infection rates (TB-HIV) signifies the percentage of people concurrently infected with TB and HIV. An uptick in such co-infections arises due to the impaired immune system triggered by HIV, which heightens the susceptibility to TB, coupled with the global overlapping of the two epidemics among vulnerable populations. Tuberculosis therapeutics play an essential role in managing the escalating co-infection rates (TB-HIV), by offering specialized treatment plans that tackle both the TB infection and the HIV-induced immune suppression. This improves the overall prognosis of patients, easing the strain of both diseases. For instance, the UK-based public sector, as per gov.uk, declared in October 2023, that England registered 3,805 fresh HIV diagnoses, marking a significant leap of 22% from the 3,118 cases reported in 2021. Hence, the upsurge in co-infection rates (TB-HIV) is a major driving factor in the expansion of the tuberculosis therapeutics market.

Which Key Market Segments Comprise the Tuberculosis Therapeutics Market and Drive Its Revenue Growth?

The tuberculosis therapeuticsmarket covered in this report is segmented –

1) By Type: Active Tuberculosis (TB); Latent Tuberculosis (TB)

2) By Product Type: Isoniazid; Rifampin; Pyrazinamide; Hydrazine derivatives; Miscellaneous anti-tubercular drugs; Ethambutol

3) By Route of Administration: Oral; Parenteral; Other route of administration

4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy

5) By End-User: Hospitals; Clinics; Ambulatory Surgical Centers; Other End-Users

Subsegments:

1) By Active Tuberculosis (TB): First-Line Drugs (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol); Second-Line Drugs (Fluoroquinolones, Aminoglycosides); Combination Therapies; Drug-Resistant TB Treatments (MDR-TB, XDR-TB)

2) By Latent Tuberculosis (TB): Isoniazid Prophylaxis; Rifampicin-Based Regimens; Rifapentine-Based Regimens; Combination Prophylactic Therapies

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=20983&type=smp

Which Areas Are Leading Regions in the Tuberculosis Therapeutics Market Expansion Across the Globe?

North America was the largest region in the tuberculosis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tuberculosis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in theTuberculosis Therapeutics Market Over the Coming Years?

Major corporations in the tuberculosis therapeutics market have begun concentrating on creating unique solutions, such as combination therapy, to enhance the effectiveness of treatments, shorten the period of therapy, and fight against tuberculosis drug-resistant strains. The term combination therapy refers to the application of two or more different class medications to cure a disease with the goal of boosting treatment effectiveness, minimizing resistance, and enhancing patient outcomes. For example, Johnson & Johnson, a pharmaceutical firm based in the US, hit a significant landmark in tuberculosis treatment in July 2024 when SIRTURO (bedaquiline) received approval from both the U.S. FDA and the European Commission. This innovative medication is the first in more than 40 years explicitly intended to combat multidrug-resistant tuberculosis (MDR-TB). It has a unique mechanism of action that targets the ATP synthase enzyme necessary for the energy production of TB bacteria, providing a targeted and efficient therapeutic approach. Incorporating this drug into combination therapies increases the overall efficacy of MDR-TB programs, reducing the length of treatment while also improving patient adherence to the regimen.

View the full report here:

https://www.thebusinessresearchcompany.com/report/tuberculosis-therapeutics-global-market-report

How Is the Tuberculosis Therapeutics Market Conceptually Defined?

Tuberculosis therapeutics refers to the pharmaceutical treatments designed to prevent and cure tuberculosis (TB), a bacterial infection caused by Mycobacterium tuberculosis. The purpose of these therapeutics is to eradicate the bacteria, reduce transmission, and improve patient outcomes, particularly for those with drug-resistant strains.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20983

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model